Etiology and antimicrobial resistance patterns of sepsis in infants 0-59 days old in Jimma, Ethiopia: a longitudinal study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Sepsis*/microbiology ; Sepsis*/drug therapy ; Sepsis*/etiology ; Sepsis*/epidemiology ; Sepsis*/mortality ; Anti-Bacterial Agents*/therapeutic use ; Anti-Bacterial Agents*/pharmacology ; Drug Resistance, Bacterial*; Ethiopia/epidemiology ; Staphylococcus aureus/drug effects ; Staphylococcus aureus/isolation & purification ; Humans ; Infant ; Infant, Newborn ; Male ; Female ; Prospective Studies ; Longitudinal Studies ; Microbial Sensitivity Tests

Introduction: In Ethiopia, empiric treatment for sepsis or possible serious bacterial infection (PSBI) in infants 0-59 days old is based on World Health Organization (WHO) guidelines. We aimed to assess the etiology, antimicrobial susceptibility and outcomes of empiric treatment in PSBI in Jimma, Ethiopia and created local antibiograms to assess empiric treatment guidelines in this setting.
Methods: We prospectively enrolled 363 infants 0-59 days of age admitted to Jimma University Hospital with PSBI over 12-months. Following institutional practice, blood and cerebrospinal fluid (CSF) cultures were collected; positive cultures were identified and evaluated for antibiotic susceptibility. We compared microbiologic results to the WHO guideline based empiric treatment selections at the hospital and evaluated the clinical outcomes at discharge and 30-days of age.
Results: Of 279 patients who had blood cultures obtained, 212(76.0%) were positive, yielding 216 isolates. Four CSF cultures were positive and were included in analysis of blood cultures due to the smaller number of isolates. The most common isolates were Klebsiella (31.8%), coagulase-negative Staphylococci (24.6%), and Staphylococcus aureus (11.6%). Of Klebsiella species, 87% were resistant to at least one commonly utilized antibiotic and 82% were resistant to first-line empiric antimicrobials. In-hospital mortality was 12.3% and it was highest (41%) in participants with Klebsiella. At 30-days of age, mortality for infants with positive culture was 6.6%.
Conclusions: Isolates from PSBI showed high rates of antibiotic resistance to first- and second-line antimicrobials. In this setting, the WHO empiric treatment guidelines inadequately treat infants admitted with PSBI, particularly those with Klebsiella. To provide the most effective care for PSBI in 0-59 days old infants, institutionally used guidelines should be customized to reflect local epidemiology and resistance patterns.
(© 2025. The Author(s).)

Declarations. Competing interests: James H. Conway: research funding from US Centers for Disease Control to study viral transmission in Wisconsin schools; scientific consulting agreements with: Pfizer, Merck, Moderna and GSK vaccine programs – no relation between those projects and this work. All other authors have no any conflict of interest related to the work.

Ann Trop Paediatr. 2005 Jun;25(2):101-10. (PMID: 15949198)
Arch Dis Child. 2020 Jan;105(1):26-31. (PMID: 31446393)
PLoS One. 2021 Aug 9;16(8):e0255210. (PMID: 34370744)
PLoS Med. 2023 Jun 8;20(6):e1004179. (PMID: 37289666)
Sci Rep. 2020 Jul 29;10(1):12689. (PMID: 32728110)
BMC Pediatr. 2017 Jun 6;17(1):137. (PMID: 28587631)
Lancet. 2015 May 2;385(9979):1767-1776. (PMID: 25842221)
Ann Clin Microbiol Antimicrob. 2012 Mar 26;11:7. (PMID: 22449249)
South Med J. 2011 Jul;104(7):509-14. (PMID: 21886051)
Ann Clin Microbiol Antimicrob. 2017 Sep 19;16(1):63. (PMID: 28927452)
Int J Med Microbiol. 2014 Jul;304(5-6):513-20. (PMID: 24881963)
Arch Dis Child. 2013 Feb;98(2):146-54. (PMID: 23142784)
Antimicrob Resist Infect Control. 2023 Aug 30;12(1):86. (PMID: 37649060)
Ethiop Med J. 2010 Jan;48(1):11-21. (PMID: 20607993)
J Paediatr Child Health. 2011 Jan;47(1-2):5-11. (PMID: 20973858)
Matern Health Neonatol Perinatol. 2018 Apr 18;4:8. (PMID: 29713491)
Future Microbiol. 2015;10(11):1859-79. (PMID: 26517189)
Popul Health Metr. 2016 Nov 14;14:42. (PMID: 27891065)
PLoS One. 2021 Feb 5;16(2):e0244192. (PMID: 33544712)
Lancet Infect Dis. 2021 Dec;21(12):1677-1688. (PMID: 34384533)

Keywords: Antimicrobial resistance; Infants; Neonates; Outcome; Possible serious bacterial infections; Sepsis

0 (Anti-Bacterial Agents)

Date Created: 20250927 Date Completed: 20250927 Latest Revision: 20250930

20260130

PMC12465210

10.1186/s13756-025-01626-2

41013659